Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review
October 26, 2023 10:00 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide...
Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
September 25, 2023 09:42 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been made by...
Nymox Reports Completion of $2 Million Private Placement
August 29, 2023 13:14 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the completion of its recently reported private...
Nymox Announces $2 Million Private Placement
August 02, 2023 12:21 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce an investment of US $2.0 million for 2 million shares...
Nymox's 3-month ex-CFO was Awarded an Unauthorized and Undisclosed Treasury Directive for 100,000 Shares of Nymox Stock Without the Knowledge or Approval of the Nymox Board or Nymox’s CEO
July 31, 2023 10:50 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) reports that Chris Riley, who was terminated in June of this year after only...
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
July 25, 2023 10:33 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC: NYMXF] (the “Company”) is pleased to announce today important new long-term clinical trial results from the...
Nymox Reports on U.S. Patent Issuances
July 18, 2023 10:45 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents...
Nymox Update
July 13, 2023 10:16 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the...
Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
July 12, 2023 09:30 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice...
NYMOX Update
July 07, 2023 17:02 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further...